Categories: News

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, June 06, 2022 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced that Saurabh Saha, MD, PhD, Chief Executive Officer and Gregory Weinhoff, MD, Chief Financial Officer, will participate in the following investor conferences:

Event: Jefferies Healthcare Conference
Date: Thursday, June 9, 2022
Fireside Chat Webcast Time: 4:30 PM ET

Event: Goldman Sachs 43rd Annual Global Healthcare Conference
Date: Wednesday, June 15, 2022
Fireside Chat Webcast Time: 8:00 AM PT/ 11:00 AM ET

Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at Events & Presentations | Centessa Pharmaceuticals.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc (“Centessa”) is a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a management team with extensive R&D experience, providing direct guidance to our program teams to rapidly advance our candidates from research through all stages of development. For more information, visit www.centessa.com, which does not form part of this release.

Contact:

Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com

Staff

Recent Posts

Proper Good, Inc. Successfully Secures New Funding to Fuel Growth

AUSTIN, Texas, Jan. 13, 2025 /PRNewswire/ --  Proper Good, Inc., a leader in ready-to-eat meal solutions,…

4 minutes ago

Ex-Deep Genomics, Moderna Execs Get Backing Led by Gradient to Develop Next-Generation mRNA Therapeutics with AI

SAN FRANCISCO, Jan. 13, 2025 /PRNewswire/ -- Kerna Laboratories Inc, a San Francisco-based AI biotech startup,…

4 minutes ago

Ventra Health Appoints Sarah Herzog President of Radiology as ADVOCATE RCM Integration is Completed

Former ADVOCATE RCM Head of Operations to Lead Radiology Business Unit Focused on Optimizing Performance…

4 minutes ago

Human Longevity, Inc. and SleepScore Labs Partner to Launch AI Driven Personalized Precision Sleep Program

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Human Longevity, Inc. (HLI) and SleepScore…

4 minutes ago

EDETEK Unveils Revolutionary Life Sciences R&D Cloud for Clinical Development

Unveiling the next generation paradigm in Clinical Data Sciences PRINCETON, N.J., Jan. 13, 2025 /PRNewswire/…

4 minutes ago

Vevo Therapeutics to Open Source Milestone Tahoe-100M Dataset

Tahoe-100M is the world's largest single-cell atlas of how drug molecules impact biology of patient…

4 minutes ago